Summary by Moomoo AI
Vivos Therapeutics, Inc., a company specializing in medical devices and procedures for treating sleep-disordered breathing, has filed an amended Schedule 13G/A with the SEC, indicating changes in ownership by significant shareholders. The filing, dated December 31, 2023, and submitted on February 14, 2024, reveals that Coronado V Partners, LLC and R. Kirk Huntsman, the President of Coronado V Partners, LLC, collectively hold a significant portion of the company's shares. Coronado V Partners, LLC owns 69,600 shares, representing 3.2% of the company's common stock, while R. Kirk Huntsman individually holds 94,794 shares, accounting for 4.3% of the common stock. The total shares outstanding of Vivos Therapeutics' common stock are 2,207,651 as of February 13, 2024. The filing also notes that the reported share amounts and percentages reflect the effects of a 1-for-25 reverse stock split that took effect on October 25, 2023. Additionally, the filing indicates that R. Kirk Huntsman has ceased to be the beneficial owner of more than five percent of the class of securities.